keyword
MENU ▼
Read by QxMD icon Read
search

HCV guidelines

keyword
https://www.readbyqxmd.com/read/29783148/comparative-study-of-six-sequential-spectrophotometric-methods-for-quantification-and-separation-of-ribavirin-sofosbuvir-and-daclatasvir-an-application-on-laboratory-prepared-mixture-pharmaceutical-preparations-spiked-human-urine-spiked-human-plasma-and-dissolution
#1
Wafaa S Hassan, Manal S Elmasry, Heba M Elsayed, Dalia W Zidan
In accordance with International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines, six novel, simple and precise sequential spectrophotometric methods were developed and validated for the simultaneous analysis of Ribavirin (RIB), Sofosbuvir (SOF), and Daclatasvir (DAC) in their mixture without prior separation steps. These drugs are described as co-administered for treatment of Hepatitis C virus (HCV). HCV is the cause of hepatitis C and some cancers such as liver cancer (hepatocellular carcinoma) and lymphomas in humans...
May 18, 2018: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
https://www.readbyqxmd.com/read/29779005/hbv-and-hcv-test-uptake-and-correlates-among-men-who-have-sex-with-men-in-china-a-nationwide-cross-sectional-online-survey
#2
Thomas Fitzpatrick, Stephen W Pan, Weiming Tang, Wilson Guo, Joseph D Tucker
OBJECTIVES: Hepatitis B virus (HBV) and hepatitis C virus (HCV) cause substantial morbidity and mortality in low-income and middle-income countries, including China. WHO guidelines recommend men who have sex with men (MSM) receive HBV and HCV screening. The purpose of this study was to determine the proportion of MSM in China who have HBV and HCV tested and identify correlates of test uptake. METHODS: We conducted an online cross-sectional survey of young MSM in China...
May 19, 2018: Sexually Transmitted Infections
https://www.readbyqxmd.com/read/29773899/management-of-acute-hcv-infection-in-the-era-of-direct-acting-antiviral-therapy
#3
REVIEW
Marianne Martinello, Behzad Hajarizadeh, Jason Grebely, Gregory J Dore, Gail V Matthews
The management of acute HCV infection has not been standardized following the availability of direct-acting antiviral agents (DAAs) for chronic HCV infection, and substantial uncertainty exists regarding the optimal treatment regimen and duration. Despite the lack of direct evidence, the 2016 American Association for the Study of Liver Diseases (AASLD)-Infectious Diseases Society of America (IDSA) guidelines supported "the same regimens for acute HCV as recommended for chronic HCV infection … owing to high efficacy and safety", whereas the 2016 European Association for the Study of the Liver (EASL) guidelines recommended sofosbuvir-ledipasvir, sofosbuvir-velpatasvir or sofosbuvir plus daclatasvir for 8 weeks in acute HCV infection, with a longer duration of 12 weeks recommended for those infected with HIV and/or baseline HCV RNA levels >1,000,000 IU/ml...
May 17, 2018: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29769038/impact-of-new-daa-therapy-on-real-clinical-practice-a-multicenter-region-wide-cohort-study
#4
Simone Lanini, Paola Scognamiglio, Alessandra Mecozzi, Lorella Lombardozzi, Vincenzo Vullo, Mario Angelico, Antonio Gasbarrini, Gloria Taliani, Adolfo Francesco Attili, Carlo Federico Perno, Adriano De Santis, Vincenzo Puro, Fabio Cerqua, Gianpiero D'Offizi, Adriano Pellicelli, Orlando Armignacco, Francesco Saverio Mennini, Massimo Siciliano, Enrico Girardi, Vincenzo Panella, Giuseppe Ippolito
BACKGROUND: Management of chronic hepatitis C (CHC) has significantly accelerated in the last few years. Currently, second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients. Here we present the results of the first analysis carried out on data of Lazio clinical network for DAAs. METHODS: The study was designed as a multicenter cohort: a) to assess the evolution of treatment during the first 24 months of the activity of the Clinical Network; b) to report overall efficacy of treatments; c) to analyze potential factors associated with lack of virological response at 12 weeks after therapy (SVR12); d) to evaluate the variation of ALT at baseline and 12 weeks after therapy in those who achieved SVR12 in comparison to those who did not...
May 16, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29765698/the-epidemiology-of-hepatitis-c-virus-in-pakistan-systematic-review-and-meta-analyses
#5
Zaina Al Kanaani, Sarwat Mahmud, Silva P Kouyoumjian, Laith J Abu-Raddad
To characterize hepatitis C virus (HCV) epidemiology in Pakistan and estimate the pooled mean HCV antibody prevalence in different risk populations, we systematically reviewed all available records of HCV incidence and/or prevalence from 1989 to 2016, as informed by the Cochrane Collaboration Handbook. This systematic review was reported following the PRISMA guidelines. Populations were classified into six categories based on the risk of exposure to HCV infection. Meta-analyses were performed using DerSimonian and Laird random-effects models with inverse variance weighting...
April 2018: Royal Society Open Science
https://www.readbyqxmd.com/read/29729258/compliance-with-hepatocellular-carcinoma-surveillance-guidelines-associated-with-increased-lead-time-adjusted-survival-of-patients-with-compensated-viral-cirrhosis
#6
Charlotte Costentin, Richard Layese, Valérie Bourcier, Carole Cagnot, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor De Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean-Pierre Bronowicki, Jean-Pierre Zarski, Ghassan Riachi, Paul Calès, Jean-Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean-Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean-Didier Grangé, Pierre Attali, Yannick Bacq, Claire Wartelle, Thông Dao, Dominique Thabut, Christophe Pilette, Christine Silvain, Christos Christidis, Eric Nguyen-Khac, Brigitte Bernard-Chabert, David Zucman, Vincent Di Martino, Angela Sutton, Eric Letouzé, Sandrine Imbeaud, Jessica Zucman-Rossi, Etienne Audureau, Françoise Roudot-Thoraval, Pierre Nahon
BACKGROUND AND AIMS: Semi-annual surveillance for hepatocellular carcinoma (HCC) is recommended for patients with cirrhosis. We aimed to determine how compliance with HCC surveillance guidelines affects survival times of patients with hepatitis C virus (HCV)- or HBV-associated compensated cirrhosis who developed HCC. METHODS: We collected data from the prospective ANRS CO12 CirVir study, from March 2006 through June 2012, on 1671 patients with biopsy-proven viral cirrhosis and no previous liver complications who were undergoing surveillance for HCC at 35 centers in France...
May 2, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29716179/recent-update-of-the-2017-korean-association-for-the-study-of-the-liver-kasl-treatment-guidelines-of-chronic-hepatitis-c-comparison-of-guidelines-from-other-continents-2017-aasld-idsa-and-2016-easl
#7
Jong Eun Yeon
The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained virologic response rate and ease of administration makes the DAAs approach ideal to contribute to the complete eradication of HCV. Currently, treatment options for individual patients vary depending on the genotype or subtype of HCV, presence or absence of liver cirrhosis, previous experience of antiviral treatment or resistance associated substitutions...
May 2, 2018: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29710353/iatrogenic-hepatitis-c-virus-transmission-and-safe-injection-practices
#8
Charles M Defendorf, Sindy Paul, George J Scott
Hepatitis C virus (HCV) infection poses significant adverse health effects. Improper use of vials, needles, syringes, intravenous bags, tubing, and connectors for injections and infusions is a current preventable cause of iatrogenic HCV transmission. Numerous cases have demonstrated the need for continued vigilance and the widespread nature of this iatrogenic infection risk across a variety of medical practice settings in the United States. Failure to implement the evidence-based Centers for Disease Control and Prevention (CDC) infection prevention guidelines exposes patients to preventable harm...
May 1, 2018: Journal of the American Osteopathic Association
https://www.readbyqxmd.com/read/29702515/integrated-care-for-the-use-of-direct-acting-antivirals-in-patients-with-chronic-hepatitis-c-and-substance-use-disorder
#9
Jean-Baptiste Trabut, Camille Barrault, Hélène Charlot, Damien Carmona, Anne Bourdel, Mustapha Benslimane, Murielle François, Willy Kini-Matondo, Richard Causse, Françoise Roudot-Thoraval, Christophe Hézode
OBJECTIVES: Since little is currently known about predictors of response to direct-acting antiviral agents (DAAs) in people who inject drugs, we undertook an analysis of patients attending a hepatitis clinic with addiction services (outpatient clinics and inpatient services) to examine the outcomes associated with the treatment of difficult-to-manage patients with substance use. Our experience was based on integrated care. METHOD: A retrospective analysis was undertaken of 50 patients with hepatitis C virus (HCV) and a history of addiction who received treatment with DAAs, according to European guidelines...
April 26, 2018: Journal of Addiction Medicine
https://www.readbyqxmd.com/read/29702484/hcv-core-antigen-comes-of-age-a-new-opportunity-for-the-diagnosis-of-hepatitis-c-virus-infection
#10
REVIEW
Claudio Galli, Paul Julicher, Mario Plebani
The diagnosis of hepatitis C virus (HCV) infection has been traditionally based on the detection of the host antibody response. Although antibody assays are available in different formats and are fairly accurate, they cannot distinguish between an ongoing infection with HCV replicative activity and a past infection where HCV has been cleared, spontaneously or after a successful therapy. As a chronic infection is mostly asymptomatic until the late clinical stages, there is a compelling need to detect active HCV infection by simple and reproducible methods...
April 27, 2018: Clinical Chemistry and Laboratory Medicine: CCLM
https://www.readbyqxmd.com/read/29694794/unexpected-response-profiles-seen-in-hepatitis-c-virus-infected-patients-treated-with-sofosbuvir-plus-ribavirin-five-case-reports
#11
Komal Saleem, Braira Wahid, Amjad Ali, Shazia Rafique, Zara Naz, Sana Usman, Muhammad Idrees
Direct-acting antivirals (DAAs) have been proved as potent agents in the new era of Hepatitis C therapeutics. DAA has evolved to prove highly efficacious treatment rates and sustained virological response in hepatitis C virus (HCV)-treated patients and has shown minimal side effects, but in this study, we reported five cases that showed unusual response toward the use of DAA. The diagnosis was an unusual response of abruptly high viral titers and liver function tests (LFTs) in patients who received DAA combination therapy...
April 25, 2018: Viral Immunology
https://www.readbyqxmd.com/read/29694730/rationale-for-treating-hepatitis-c-virus-infection-in-patients-with-mild-to-moderate-chronic-kidney-disease
#12
REVIEW
Ezequiel Ridruejo, Manuel Mendizabal, Marcelo O Silva
Hepatitis C virus infection (HCV) is highly prevalent in patients with chronic kidney disease (CKD) and kidney transplant recipients. Little information exists on treatment in patients with CKD stages 2 to 3, where CKD progression might be slowed by HCV treatment. These patients are not considered a high priority for HCV treatment in most international guidelines. Although some recently published guidelines propose universal treatment, others are still recommending it only in high priority groups. In this review, we evaluate current evidence of HCV infection impact on CKD progression, on cardiovascular and metabolic risk, and the benefits of HCV infection treatment to improve cardiovascular and metabolic outcomes...
April 2018: Hemodialysis International
https://www.readbyqxmd.com/read/29692878/newly-diagnosed-hepatitis-c-in-the-us-commercially-insured-population-before-and-after-the-2012-implementation-of-expanded-screening-guidelines
#13
Bruce S Pyenson, Gabriela Dieguez, Christine Ferro, Maushumi Mavinkurve, Yuri Sanchez Gonzalez
Background: In the United States in 2014, more than 3 million individuals were estimated to have chronic hepatitis C virus (HCV) infection, including many undiagnosed individuals. In 2012, the Centers for Disease Control and Prevention expanded its HCV testing recommendations to target all adults born between 1945 and 1965, in addition to at-risk individuals, which has led to an increase in newly diagnosed patients. Few studies have explored the medical cost or clinical status of patients who are newly diagnosed with HCV...
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29689073/liver-disease-burden-and-required-treatment-expenditures-for-hepatitis-c-virus-hcv-infection-in-thailand-implications-for-hcv-elimination-in-the-new-therapeutic-era-a-population-based-study
#14
Rujipat Wasitthankasem, Preeyaporn Vichaiwattana, Nipaporn Siripon, Nawarat Posuwan, Chompoonut Auphimai, Sirapa Klinfueng, Napha Thanetkongtong, Viboonsak Vuthitanachot, Supapith Saiyatha, Chaiwat Thongmai, Saowakon Sochoo, Natnada Pongsuwan, Kittiyod Poovorawan, Pisit Tangkijvanich, Yong Poovorawan
The prevalence of hepatitis C virus (HCV) infection has been decreasing globally, but the growing effects of HCV-related morbidity and mortality remain of concern. Advances in curative medicine, involving direct-acting antivirals (DAAs), have led many countries to aim to eradicate HCV. Information on epidemiology and disease burden is essential for national policy development. Thus, this study aimed to determine the HCV-related hepatic disease burden in areas of Thailand with high and average HCV prevalence in order to extrapolate the viral burden across Thailand...
2018: PloS One
https://www.readbyqxmd.com/read/29681166/direct-acting-antivirals-to-prevent-vertical-transmission-of-viral-hepatitis-c-when-is-the-optimal-time-to-treat
#15
Leigh Cervino, Lauren M Hynicka
OBJECTIVE: To describe the most current evidence for the use of direct-acting antivirals (DAAs) to treat hepatitis C along the pregnancy-pediatric continuum in the United States. DATA SOURCES: The MEDLINE/PubMed databases were searched (January 1995 to February 2018) for articles in English using the terms: hepatitis C, vertical transmission, pregnancy, pediatrics, ribavirin, interferon, direct acting antivirals, daclatasvir, dasabuvir, elbasvir, glecaprevir, grazoprevir, ledipasvir, ombitasvir, paritaprevir, pibrentasvir, simeprevir, sofosbuvir, and velpatasvir...
April 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29661260/implementing-routine-blood-borne-virus-testing-for-hcv-hbv-and-hiv-at-a-london-emergency-department-uncovering-the-iceberg
#16
S Parry, N Bundle, S Ullah, G R Foster, K Ahmad, C Y W Tong, S Balasegaram, C Orkin
UK guidelines recommend routine HIV testing in high prevalence emergency departments (ED) and targeted testing for HBV and HCV. The 'Going Viral' campaign implemented opt-out blood-borne virus (BBV) testing in adults in a high prevalence ED, to assess seroprevalence, uptake, linkage to care (LTC) rates and staff time taken to achieve LTC. Diagnosis status (new/known/unknown), current engagement in care, and severity of disease was established. LTC was defined as patient informed plus ⩾1 clinic visit. A total of 6211/24 981 ED attendees were tested (uptake 25%); 257 (4...
April 17, 2018: Epidemiology and Infection
https://www.readbyqxmd.com/read/29611014/cost-effectiveness-of-novel-treatment-of-hepatitis-c-virus-in-lebanese-patients
#17
Soumana C Nasser, Hanine Mansour, Tatiana Abi Nader, Mirna Metni
Background Limited data is available on Hepatitis C disease prevalence, treatment initiation and its cost-effectiveness in Lebanon and the whole Middle East. Objective The aim of the study is to assess whether initiation of novel Direct Acting Antiviral agents (DAAs) at early stage of hepatitis C is cost-effective in Lebanese patients. Setting Lebanon. Methods This modeling study was conducted from the perspective of Lebanese third party payers, where existing practice is based on international guidelines for the diagnosis and treatment of diseases...
April 2, 2018: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/29568202/differing-profiles-of-people-diagnosed-with-acute-and-chronic-hepatitis-b-virus-infection-in-british-columbia-canada
#18
Mawuena Binka, Zahid A Butt, Stanley Wong, Mei Chong, Jane A Buxton, Nuria Chapinal, Amanda Yu, Maria Alvarez, Maryam Darvishian, Jason Wong, Gina McGowan, Mikhail Torban, Mark Gilbert, Mark Tyndall, Mel Krajden, Naveed Z Janjua
AIM: To describe the characteristics of people diagnosed with acute and chronic hepatitis B virus (HBV) infection in British Columbia (BC). METHODS: We used data from the BC Hepatitis Testers Cohort (BC-HTC), which includes all individuals tested for hepatitis C virus (HCV) or human immunodeficiency virus (HIV) or those diagnosed with HBV or active tuberculosis in BC since 1990. These data were integrated with prescription drug, medical visit, hospitalization and mortality data...
March 21, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29566611/treatment-of-hcv-in-the-department-of-corrections-in-the-era-of-oral-medications
#19
Richard K Sterling, Reena Cherian, Shawn Lewis, Kathleen Genther, Carolyn Driscoll, Kelly Martin, Mary Beth Goode, Scott Matherly, Mohammad S Siddiqui, Velimir A Luketic, R Todd Stravitz, Puneet Puri, Hannah Lee, Paula Smith, Vaishali Patel, Arun J Sanyal
Chronic hepatitis C virus (HCV) is widely prevalent in the Virginia Department of Corrections (DOC). However, sustained virologic response (SVR) with all oral direct-acting antiviral (DAA) therapy is unknown. HCV treatment was provided through telemedicine following guidelines of the American Association for the Study of Liver Diseases and Infectious Diseases Society of America. SVR12 in the DOC was compared in two control groups: privately insured and indigent patients receiving care in HCV treatment clinics by the same providers during the same time period...
January 1, 2018: Journal of Correctional Health Care
https://www.readbyqxmd.com/read/29564364/risk-based-hepatitis-c-screening-in-pregnancy-is-less-reliable-than-universal-screening-a-retrospective-chart-review
#20
Sarah Boudova, Katrina Mark, Samer S El-Kamary
Current guidelines recommend only hepatitis C virus (HCV) risk-based screening during pregnancy. We examined screening practices at a major medical center and found inconsistent risk-based screening and the presence of HCV among women with no known risk factors. We make a case for the implementation of universal HCV screening during pregnancy.
March 2018: Open Forum Infectious Diseases
keyword
keyword
64824
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"